Navigation Links
Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
Date:5/31/2011

ia (Ph+ CML) in chronic phase. The effectiveness of Tasigna for this indication is based on major molecular response and cytogenetic response rates at 12 months. The study is ongoing and further data will be required to determine long-term outcome.

Tasigna® (nilotinib) 200 mg capsules is also approved in more than 90 countries for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including Gleevec. The effectiveness of Tasigna for this indication is based on hematologic and cytogenetic response rates.

TASIGNA BOXED WARNING and Additional Important Safety InformationTASIGNA (nilotinib) prolongs the QT interval. Sudden deaths have been reported in patients receiving TASIGNA. TASIGNA should not be used in patients with hypokalemia, hypomagnesemia, or long QT syndrome. Hypokalemia or hypomagnesemia must be corrected prior to TASIGNA administration and should be periodically monitored. Drugs known to prolong QT interval and strong CYP3A4 inhibitors should be avoided. Patients should avoid food 2 hours before and 1 hour after taking dose. A dose reduction is recommended in patients with hepatic impairment.

ECGs should be obtained to monitor the QTc at baseline, 7 days after initiation and periodically thereafter, as well as following any dose adjustments.

  • Treatment with TASIGNA can cause Grade 3/4 thrombocytopenia, neutropenia and anemia. Complete blood counts should be performed every 2 weeks for the first 2 months and then monthly thereafter.

  • Caution is recommended in patients with a history of pancreatitis.

  • The use of TASIGNA may result in elevations in bilirubin, AST/ALT and alkaline phosphatase.

  • TASIGNA can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia and hyponatremia (see Boxed WARNING).

  • The concomitant use of strong CYP3A4 inhibitors or anti-arrhythmic drugs (includ
    '/>"/>

  • SOURCE Novartis Pharmaceuticals Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

    Related medicine technology :

    1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
    3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
    4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
    5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
    6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
    7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
    8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
    9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
    10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
    11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/22/2014)... , Aug. 22, 2014 MC Medical, a subsidiary ... a Columbus, OH medical device company, ... FloShield laparoscopic and robotic visualization system in Japan ... for sale in Japan in the ... experience and an extensive product portfolio in endoscopic surgery market ...
    (Date:8/22/2014)... Zacks Equity Research highlights Epizyme (Nasdaq: EPZM - Free ... PNRA - Free Report ) as the Bear of the ... (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: SNY ... Report ). Here is a synopsis of all five ... The biotech bull market is far from over due ...
    (Date:8/22/2014)... LA JOLLA , Cali ., Aug. ... Annual International Papillomavirus Conference shows that a therapy being developed ... including the two that cause 70 percent of all cervical ... models, HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 ... Thomas Broker , Ph.D., who presented the findings at ...
    Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
    ... CARMEL, Ind., Aug. 23, 2011 After several years ... device firms, Avant Healthcare Marketing has opened offices on ... expansion for the Midwest medical communications agency. ... Rod Julian, Strategic Brand Network Director for Avant. "But ...
    ... England, August 23, 2011 KalVista Pharmaceuticals ("KalVista"), ... edema (DME), has raised £8 million in a series A ... Life Sciences. The Company is developing novel, small ... the treatment of DME, a leading cause of adult visual ...
    Cached Medicine Technology:Avant Healthcare Marketing Announces West Coast Expansion 2KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema 2KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema 3KalVista Pharmaceuticals Launched With £8 Million in Series A Funding to Develop Novel Class of Drugs for Diabetic Macular Edema 4
    (Date:8/23/2014)... York (PRWEB) August 23, 2014 ... filed on behalf of individuals who were ... hip replacement line continue to move forward in ... Bernstein Liebhard LLP reports. According to an Order ... bellwether trial program that would allow the litigation’s ...
    (Date:8/23/2014)... 23, 2014 On Monday, August 18th, ... data breach suffered by Community Health Systems, which ... of 4.5 million records containing Personally Identifiable Information (PII) ... to Mandiant, who was engaged to investigate the incident, ... advanced group of cyber attackers based in China, who ...
    (Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, August 18th ... of water for commercial and industrial properties. This was ... Archworks, LLC in Carmel, California. , This is a ... district in the State of California has approved this technology ... this time can now be used as a sole source ...
    (Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut Pro ... Vol.3, a customizable title tool for FCPX , ... dragging ProIntro Vol.3 in their timeline" says Christina Austin, CEO ... saver and i think our users will agree" , ProIntro ... made with Final Cut Pro X users in mind. Achieve ...
    (Date:8/23/2014)... 2014 Dealing with a drug or alcohol ... the addict is a child. Adolescent addiction has been an ... time, but a new helpline is now providing a valuable ... to find a real addiction recovery center. , The Troubled ... impact in the community. By calling (404) 975-2762, parents and ...
    Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2
    ... ... Onset Technology® today announce a partnership agreement to provide an advanced paging solution for ... enables Citipage customers to receive pages on their Blackberry smartphone via their current pager ... ...
    ... known that certain types of bacteria boost the immune ... how bacteria perform this essential task. Senior author ... in a featured article in the June 15, 2010, ... available online. Knight is professor and chair of the ...
    ... disorder in men , MONDAY, June 14 (HealthDay News) ... insecticides may increase a man,s risk of Parkinson,s disease, ... disease patients and a control group of 482 healthy ... for mutations in a gene called ABCB1 and assessed ...
    ... some drugs, smoking increased vision problems, studies found , ... helps guard against cataracts, while certain medications raise the ... new studies suggest. , And a third study finds ... another disease that robs people of their sight. , ...
    ... around 200,000 people in Sweden have been diagnosed with ... be helped by mechanical heart pumps, reveals a thesis ... a total of 99 patients with life-threatening heart failure ... long-term circulatory support., "Two-thirds of these patients survived," says ...
    ... nurse in The University of Texas MD Anderson Cancer ... the 2010 Ethel Fleming Arceneaux Outstanding Nurse-Oncologist Award, made ... of MD Anderson,s clinical faculty, patient care administration and ... selecting Fields for the annual award, the institution,s highest ...
    Cached Medicine News:Health News:Onset Technology and Citipage Ltd. Partner to Deliver Advanced Paging Messages to Smartphones 2Health News:Onset Technology and Citipage Ltd. Partner to Deliver Advanced Paging Messages to Smartphones 3Health News:How bacteria boost the immune system 2Health News:Diet, Meds and Smoking Linked to Eye Disease Risks 2Health News:Diet, Meds and Smoking Linked to Eye Disease Risks 3Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 2Health News:Peg Fields to receive MD Anderson's highest nurse-oncologist honor 3
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: